- Home
- NDRA vs LYRA Comparison
NDRA vs LYRA Comparison
Compare NDRA & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- LYRA
- Stock Information
- Founded
- NDRA 2007
- LYRA 2005
- Country
- NDRA United States
- LYRA United States
- Employees
- NDRA N/A
- LYRA N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- LYRA Medical/Dental Instruments
- Sector
- NDRA Health Care
- LYRA Health Care
- Exchange
- NDRA Nasdaq
- LYRA Nasdaq
- Market Cap
- NDRA 7.3M
- LYRA 7.6M
- IPO Year
- NDRA 2017
- LYRA 2020
- Fundamental
- Price
- NDRA $4.53
- LYRA $3.04
- Analyst Decision
- NDRA Strong Buy
- LYRA Hold
- Analyst Count
- NDRA 1
- LYRA 1
- Target Price
- NDRA $38.00
- LYRA $16.00
- AVG Volume (30 Days)
- NDRA 45.9K
- LYRA 33.6K
- Earning Date
- NDRA 11-17-2025
- LYRA 11-12-2025
- Dividend Yield
- NDRA N/A
- LYRA N/A
- EPS Growth
- NDRA N/A
- LYRA N/A
- EPS
- NDRA N/A
- LYRA N/A
- Revenue
- NDRA N/A
- LYRA $600,000.00
- Revenue This Year
- NDRA N/A
- LYRA N/A
- Revenue Next Year
- NDRA N/A
- LYRA $106.28
- P/E Ratio
- NDRA N/A
- LYRA N/A
- Revenue Growth
- NDRA N/A
- LYRA N/A
- 52 Week Low
- NDRA $2.90
- LYRA $3.03
- 52 Week High
- NDRA $11.96
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- NDRA 42.26
- LYRA 17.59
- Support Level
- NDRA $6.06
- LYRA $5.40
- Resistance Level
- NDRA $6.80
- LYRA $3.99
- Average True Range (ATR)
- NDRA 0.84
- LYRA 0.35
- MACD
- NDRA -0.12
- LYRA -0.09
- Stochastic Oscillator
- NDRA 23.44
- LYRA 1.58
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.